Details of the Drug
General Information of Drug (ID: DMJ29MN)
Drug Name |
N-benzyl-2-oxo-2H-chromene-3-carboxamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3-(Benzylcarbamoyl)coumarin; BRN 0257384; Coumarin, 3-(benzylcarbamoyl)-; 2H-1-Benzopyran-3-carboxamide, 2-oxo-N-(phenylmethyl)-; 1846-90-8; 2-Oxo-2H-chromene-3-carboxylic acid benzylamide; 2-Oxo-N-(phenylmethyl)-2H-1-benzopyran-3-carboxamide; N-benzyl-2-oxo-2H-chromene-3-carboxamide; AC1L3R3J; Oprea1_583472; Oprea1_560940; 3-carboxamido coumarin, 36; MLS001210650; CHEMBL469976; CTK0H5459; BDBM29186; DTXSID90171596; MolPort-000-375-285; ZINC130283; HMS2837I12; STK078064; N-benzyl-2-oxochromene-3-carboxamide; AKOS002234224
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 279.29 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||